EpiTherapeutics

Developing novel innovative cancer drugs based on world leading research in epigenetics

EpiTherapeutics is a biopharmaceutical company developing novel innovative cancer drugs based on the world leading research in the field of epigenetics. EpiTherapeutics' development programs are focused on enzymes involved in the regulation of transcription in cancer - current programs target histone demethylases and methyltransferases. EpiTherapeutics is based in Denmark.

EpiTherapeutics was acquired by Gilead Sciences in 2015.